Literature DB >> 9195541

Osteoporosis clinical trials endpoints: candidate variables and clinimetric properties.

A Cranney1, P Tugwell, S Cummings, P Sambrook, J Adachi, A J Silman, W J Gillespie, D T Felson, B Shea, G Wells.   

Abstract

We reviewed evidence on endpoints used in osteoporosis clinical trials to assist in the development of a set of endpoints to be included in all trials. A MEDLINE search was conducted using the Cochrane Collaboration strategy for each endpoint. Additional published literature was obtained from content experts. A proposed list of endpoints was developed after consultation with experts in the field. Each endpoint was evaluated with respect to validity, reproducibility, redundancy, and feasibility. We classified the endpoints into 2 major categories: clinical health status outcomes and intermediate endpoints, and for each endpoint we present current evidence from the literature as pertains to defined methodologic criteria. Multiple endpoints have been used in osteoporosis clinical trials, and an agreement on a core set of measures needs to be evidence based with an emphasis on validity, reproducibility, and feasibility and to satisfy clinical credibility.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9195541

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  4 in total

Review 1.  Effects of growth hormone therapy on bone density and fracture risk in age-related osteoporosis in the absence of growth hormone deficiency: a systematic review and meta-analysis.

Authors:  Maya Barake; Asma Arabi; Nancy Nakhoul; Ghada El-Hajj Fuleihan; Sarah El Ghandour; Anne Klibanski; Nicholas A Tritos
Journal:  Endocrine       Date:  2017-10-13       Impact factor: 3.633

2.  Progression of Knee Osteoarthritis With Use of Intraarticular Glucocorticoids Versus Hyaluronic Acid.

Authors:  Justin Bucci; Xiaoyang Chen; Michael LaValley; Michael Nevitt; James Torner; Cora E Lewis; David T Felson
Journal:  Arthritis Rheumatol       Date:  2021-12-30       Impact factor: 10.995

3.  Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis.

Authors:  David A Stevenson; Elisabeth L Schwarz; David H Viskochil; Laurie J Moyer-Mileur; Mary Murray; Sean D Firth; Jacques L D'Astous; John C Carey; Marzia Pasquali
Journal:  Pediatr Res       Date:  2008-06       Impact factor: 3.756

4.  The ECOS-16 questionnaire for the evaluation of health related quality of life in post-menopausal women with osteoporosis.

Authors:  Xavier Badia; Adolfo Díez-Pérez; Raquel Lahoz; Luis Lizán; Xavier Nogués; Jordi Iborra
Journal:  Health Qual Life Outcomes       Date:  2004-08-03       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.